 LIBERTYTM Robotic System being remotely operated LIBERTYTM Robotic System being remotely operated LIBERTYTM Robotic System LIBERTYTM Robotic SystemWorlds First Fully Disposable Surgical Robot Achieved all Endpoints with No Intraoperative Adverse Events Remotely Performed Procedures have the Potential to Reduce Radiation Exposure, Physical Strain and Cross Contamination to Both the Patients and the Surgical StaffHINGHAM, Mass., Aug. 17, 2020 GLOBE NEWSWIRE -- Microbot Medical Inc. Nasdaq: MBOT, today announced the successful conclusion of its feasibility animal study using the Companys LIBERTYTM Robotic System, the worlds first fully disposable surgical robotic system. The study met all of its end points with no intraoperative adverse events, which supports the Companys objectives to allow physicians to conduct a catheter-based procedure from outside the catheterization laboratory cath-lab, avoiding radiation exposure, physical strain and the risk of cross contamination. It was performed by two leading physicians in the neuro vascular and peripheral vascular intervention spaces, and the results demonstrated robust navigation capabilities, intuitive usability and accurate deployment of embolic agents, most of which was conducted remotely from the cath-labs control room.Photos accompanying this announcement are available at continue to validate the LIBERTYTM Robotic System and confirm our assertion that it has the potential to revolutionize the robotic surgery space by democratizing endoluminal procedures with enhanced clinical and economical outcomes, commented Harel Gadot, CEO, President and Chairman. The freedom from capital equipment, coupled with the ability to operate LIBERTYTM remotely, especially in todays COVID-19 healthcare environment, will potentially reduce the cross contamination between the surgical staff and patients on top of reducing radiation exposure. Overall, we believe that we are in the right market, at the right time and with the right solution.Mr. Gadot, along with other members of the management team, will be sharing these results at the Needham Virtual Med Tech Diagnostics Conference being held today. A copy of the investor presentation, which highlights the initial results of the feasibility animal study, can be accessed via the Investors section, under Presentation Resources of the Companys website at Company believes that the LIBERTYTM Robotic System, which was unveiled in January 2020, is the worlds first fully disposable robotic system which features a unique compact design; With the capability to be operated remotely, it is being designed to reduce radiation exposure, the physical strain to the physician as well as cross contamination between the surgical staff and patients. In addition, incorporating the technology the Company acquired from CardioSert into the LIBERTYTM Robotic System, has the potential to eliminate the use of multiple consumables through its One Done capabilities.About Microbot MedicalMicrobot Medical Inc. NASDAQ: MBOT is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbots current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio MGPP.Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at HarborStatements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial andor operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects and estimates should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development andor commercialization of potential products, including LIBERTYTM, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading Risk Factors in Microbot Medicals periodic reports filed with the Securities and Exchange Commission SEC and in the prospectus supplement related to the registered direct offering to be filed with the SEC, which are or will be available on the SECs web site at Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.Investor Contact: Michael Polyviou EVC Group 732-933-2754 